GlaxoSmithKline
VerifiedScience-led global healthcare co with a special purpose: to help people to do more, feel better, live longer
Launch date
Employees
Market cap
$102.1b
Net debt
£10.3b
Firm valuation
$114.5b (Public information from Aug 2022)
Share price
$40.57 GSK
Brentford England (HQ)
Deals in current and previous year:
Corporate Venture Fund: SR One, GSK Canada Life Sciences Innovation Fund, Action Potential Venture Capital
RELATED LANDSCAPES AND LISTS
Financials
Edit| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E |
|---|---|---|---|---|---|---|---|
| Revenues | - | 36.2b | 37.0b | 40.5b | 40.9b | 40.9b | 43.3b |
| % growth | - | - | 2 % | 10 % | 1 % | - | 6 % |
| EBITDA | (10m) | 12.3b | 12.6b | 14.4b | 11.4b | 13.6b | 13.0b |
| % EBITDA margin | - | 34 % | 34 % | 35 % | 28 % | 33 % | 30 % |
| Profit | 10m | 1.8b | 4.3b | 5.6b | 6.9b | 5.3b | 6.6b |
| % profit margin | - | 5 % | 12 % | 14 % | 17 % | 13 % | 15 % |
| EV / revenue | - | 2.6x | 3.1x | 3.4x | 2.6x | 2.9x | 2.6x |
| EV / EBITDA | - | 7.6x | 9.0x | 9.5x | 9.2x | 8.8x | 8.8x |
| R&D budget | 4.0b | 4.4b | 4.1b | 5.1b | - | - | - |
| R&D % of revenue | - | 12 % | 11 % | 13 % | - | - | - |
Source: Company fillings or news article
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - Not yet verified | |
| N/A | N/A | IPO Not yet verified | |
| N/A | $7.5m | Grant Not yet verified | |
| N/A | $18m | Grant Not yet verified | |
| Total Funding | - | ||
Recent News about GlaxoSmithKline
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
ACQUISITION by GlaxoSmithKline Feb 2015
ACQUISITION by GlaxoSmithKline Apr 2008
ACQUISITION by GlaxoSmithKline May 2005
exited
exited
ACQUISITION by Teleflex Jun 2012
ACQUISITION by Pfizer May 2016
ACQUISITION by GlaxoSmithKline Aug 2012
exited